AVANIR Pharmaceuticals to Present at the C.E. Unterberg, Towbin Specialty Pharmaceutical Conference

SAN DIEGO--(BUSINESS WIRE)--Oct. 25, 2004--AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at the C.E. Unterberg, Towbin Specialty Pharmaceutical Conference taking place October 27-28, 2004 in New York. Dr. Gerald J. Yakatan, President and Chief Executive Officer, will be providing a corporate overview and a review of the Company's lead product, Neurodex(TM), for the treatment of central nervous system disorders.

Event: C.E. Unterberg, Towbin Specialty Pharmaceutical Conference

Presenter: Gerald J. Yakatan, Ph.D., Chief Executive Officer,
           AVANIR Pharmaceuticals

Date: Thursday, October 28, 2004

Time: 2:00 p.m. Eastern Time

Location: The Palace Hotel, New York City

AVANIR Pharmaceuticals is a drug discovery and development company focused on the development of treatments for chronic diseases. The Company's lead product candidate, Neurodex(TM), recently completed a second pivotal Phase III trial for the treatment of pseudobulbar affect. Neurodex(TM) is also in Phase III clinical development for the treatment of neuropathic pain. An internally developed small molecule, AVP-13358, is in a Phase I clinical trial for the treatment of allergy and asthma. Preclinical programs include small molecule research in atherosclerosis and inflammation. AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, 858-622-5202 (Investor Relations)

    SOURCE: AVANIR Pharmaceuticals